Thanks hottod, lots of useful info as always. I was intrigued by your note that Stoke only have one drug in clinical trials, with a prevalence of 1:15,700. They have 4 others in pre-clinical. It's market cap is A$1.13B.
PYC seems to have a stronger pipeline, but valued at A$780m. Just interesting to see the differences.
Three things possibly holding back PYC at the moment:
- Being in Australia - biotech backwater (from a financial perspective)
- Being low on cash - cap raise or deal..?
- Lack of exposure to build the buy-side
Hoping the next 6 months changes the last 2...?
Thanks again.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.33 |
Change
0.080(6.43%) |
Mkt cap ! $772.8M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.35 | $1.21 | $763.8K | 595.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 97719 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 6599 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| PYC (ASX) Chart |